An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

Leukemia
U JehnV Heinemann

Abstract

Long-term results of both pretreated and previously untreated patients (pts) with hairy cell leukemia (HCL) using uniformly a single 7-day course of 2-chlorodeoxyadenosine (2-CdA) by continuous infusion are reported. In addition, the probability of obtaining another response with this drug in pts who relapsed after 2-CdA treatment will be addressed. A total of 44 consecutive pts (34 males, 10 females) with a median age of 57 years (range 33-77) at the time of initiation of 2-CdA treatment were analyzed. In all, 11 pts were pretreated with either splenectomy (n=6), interferon alpha (n=9) or deoxycoformycin (dCF) (n=3) or all procedures in sequence. Two pts treated with dCF did not respond to dCF, but only 2-CdA. The median time to the start of 2-CdA treatment of the 11 pretreated pts was 47 months (mo) (10-160). Out of 44, 43 (98%) achieved complete response (CR) (13 pts with residual disease-RD), one pt reached a good partial response with a single cycle of 2-CdA. Out of 44 pts, 13 had no nonhematologic toxicities at all. Toxicities (WHO grade I-IV) were mainly of grade I and II, in one pt grade IV infectious complication. Bone marrow biopsies were performed at the time of recovery of hematopoiesis, thereafter at 2-3 mo interva...Continue Reading

References

Nov 1, 1978·Annals of Internal Medicine·H M GolombD W Golde
Apr 19, 1990·The New England Journal of Medicine·L D PiroE Beutler
Apr 2, 1987·The New England Journal of Medicine·A S SpiersM J O'Connell
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D HoP Stryckmans
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonE Beutler
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A HoffmanK R Rai
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockM Talpaz
Apr 22, 1999·Annals of Hematology·U JehnV Heinemann
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonB Freidlin
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoUNKNOWN Italian Cooperative Group for the Study of Hairy Cell Leukemia
Jun 21, 2003·Blood·Deborah A ThomasHagop M Kantarjian

❮ Previous
Next ❯

Citations

Aug 4, 2007·Medical Oncology·Ronan Swords, Francis Giles
Jul 20, 2006·Gut·X DrayB Messing
Jan 6, 2006·American Journal of Clinical Pathology·Yi-Hua ChenLoAnn Peterson
Apr 14, 2012·Indian Journal of Pathology & Microbiology·Komal S GalaniSumeet Gujral
Feb 18, 2014·Blood Cancer Journal·V MaevisI G H Schmidt-Wolf
Mar 22, 2014·Current Treatment Options in Oncology·Preetesh JainFarhad Ravandi
Apr 23, 2014·Annals of Hematology·Pier Luigi ZinzaniLisa Argnani
Dec 30, 2014·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Venkatesan SomasundaramRenu Saxena
Aug 31, 2013·Der Internist·L H Lindner, W Hiddemann
Jan 8, 2015·Leukemia & Lymphoma·Preetesh JainFarhad Ravandi
Jun 1, 2011·Leukemia & Lymphoma·Stephen E SpurgeonElliot M Epner
Nov 17, 2006·Leukemia & Lymphoma·Adi Gidron, Martin S Tallman
May 27, 2011·Leukemia & Lymphoma·Claire E DeardenDaniel Catovsky
Oct 21, 2009·Leukemia & Lymphoma·Michael R Grever, Pier Luigi Zinzani
Oct 21, 2009·Leukemia & Lymphoma·Robert J KreitmanIra Pastan
Aug 26, 2014·Expert Review of Hematology·Zheng Z Topp, Alan Saven
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Constantin A Dasanu, Doru T Alexandrescu
Jul 17, 2009·Expert Opinion on Investigational Drugs·Stephen SpurgeonElliot M Epner
Jan 4, 2012·Mayo Clinic Proceedings·Rahul R Naik, Alan Saven
Sep 26, 2009·Clinical Lymphoma & Myeloma·Farhad Ravandi
Jun 12, 2009·Seminars in Oncology·Hagop M Kantarjian
Dec 14, 2005·Mayo Clinic Proceedings·Farhad Ravandi, Susan O'Brien
Jan 12, 2008·Clinical Lymphoma & Myeloma·Patricia Martín-JiménezMarcos González
Mar 19, 2008·Disease-a-month : DM·Helen Enright, Jonathan Bond
Sep 23, 2006·Hematology/oncology Clinics of North America·Rajesh Belani, Alan Saven
Sep 23, 2006·Hematology/oncology Clinics of North America·Deborah A ThomasHagop Kantarjian
Sep 23, 2006·Hematology/oncology Clinics of North America·Adi Gidron, Martin S Tallman
Nov 29, 2015·Best Practice & Research. Clinical Haematology·Monica ElseDaniel Catovsky
Jul 3, 2010·Cancer·Pier Luigi ZinzaniMichele Baccarani
Mar 26, 2014·British Journal of Haematology·Francine Garnache OttouElizabeth Macintyre
Oct 10, 2009·British Journal of Haematology·Rudolf BenzJoerg Fehr
Jun 21, 2005·Blood Reviews·Farhad Ravandi, Susan O'Brien
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Peter H Wiernik
Sep 18, 2012·Clinical Lymphoma, Myeloma & Leukemia·Naval DaverFarhad Ravandi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.